Navigation Links
DyCE(TM) (Dynamic Contrast Enhancement) Technology Now Part of CRi's Analysis Software Suite for the Popular Maestro(TM) in vivo Molecular Imaging System
Date:3/20/2008

WOBURN, Mass., March 20 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi) is shipping DyCE(TM) (Dynamic Contrast Enhancement), a new technology application, to users of the award-winning Maestro(TM) in vivo molecular imaging system. Customers can now generate all- optical anatomical images of mouse models in only a few minutes, saving time and enabling better time-resolved images of molecular probe distribution.

CRi has an exclusive commercialization agreement with Massachusetts General Hospital (MGH) for its DyCE application which received widespread acclaim when introduced at the recent Society of Molecular Imaging/Academy of Molecular Imaging joint conference for in vivo imaging. DyCE was also featured in the cover article in Nature Photonics in August of 2007.

"DyCE is a quantum leap forward for optical imaging, poised to revolutionize in vivo fluorescence imaging," says James Mansfield, Director of Multispectral Imaging Systems at CRi. "Our customers can now produce anatomical images in record time and also save significant money versus conventional means."

Anatomical images are produced using DyCE in the following way. A bolus of an inert near-infrared dye (such as indocyanine green) is injected, and then a time-based series of data is collected. Using CRi's analysis software, this data set is interpreted to delineate most of the major organ systems, using optical imaging alone. This organ-specific imaging is possible, because organs have characteristic uptake or distribution patterns over time that can be 'illuminated' by the dye passing through, distinguishing them from other structures.

These in vivo anatomical maps can be overlaid co-registered with simultaneously acquired images of a targeted molecular probe to delineate the marker's specific anatomical and physical location at any time point in the study.

"CRi is uniquely positioned to commercialize DyCE capitalizing on the combination of our advanced multispectral in vivo imaging systems and our industry-leading data analysis tools," explains George Abe, CRi's President and CEO.

"We are pleased to partner with the Massachusetts General Hospital in this endeavor and are excited to enable our customers to further advance their small animal imaging capabilities", continued Abe.

CRi will be exhibiting the latest automated Maestro 2 system featuring DyCE along with CRi's cellular imaging solutions at the Annual Meeting of the American Association for Cancer Research (AACR), April 12 to 16 (Booth 235). Attendees can make an appointment to meet with a sales or technical representative by e-mailing aacr@cri-inc.com or calling (Toll-Free US) 1-800- 383-7924.

CRi is a Boston-based biomedical imaging company providing innovative optical imaging solutions to our customers for more than 20 years. Our multidisciplinary team is dedicated to working with our academic and commercial customers to provide high-value solutions. We provide comprehensive imaging and analysis solutions that enable the user to investigate and characterize biological phenotypes while preserving spatial context. CRi's innovative solutions encompass sub-cellular, cellular and whole animal applications, and are being utilized around the world to enable breakthroughs in research, health and medicine.

For more information visit our website at http://www.cri-inc.com or contact:

Ross Nakatsuji

CRi Marketing/Sales Group Leader

35-B Cabot Road, Woburn, MA 01801 USA

(P) 1-781-935-9099, extension 177

(C) 1-781-405-4000

(E) rnakatsuji@cri-inc.com


'/>"/>
SOURCE Cambridge Research & Instrumentation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Omniscan
2. Allergic reactions to gadolinium-based contrast agents are rare, study finds
3. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
4. Stem Cell Technology Offers Promise of Huge Savings for Drug Developers
5. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
6. New England Technology Foundation Announces Connecting for Childrens Charities 2008 Event
7. Healthcare Tech and the World: Personalized Technology to Benefit Healthcare Consumers in the Future
8. RIVAs Cutting Edge Technology To Help Intermountain Healthcare Enhance Medication Delivery Safety
9. New Technology No Better at Spotting Anesthesia Awareness
10. Virtual reality and computer technology improve stroke rehabilitation
11. Advanced Technology in Dental Imaging Benefits Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Mt. ... launch of a months-long rebranding effort. This includes the introduction of new packaging ... discussions and market research, we learned that a simple, proactive approach to wellness ...
(Date:3/27/2017)... PORT RICHEY, Fla. (PRWEB) , ... March 27, ... ... U.S. drug overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 ... Assemblyman Kevin McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax ...
(Date:3/26/2017)... ... March 26, 2017 , ... ... the RealSelf 100 Award, a prestigious award honoring the top influencers on RealSelf—the ... find and connect with doctors and clinics. , In 2016, more than 82 ...
(Date:3/24/2017)... ... 2017 , ... Clean Earth, Inc., a leader in providing ... materials announced today the acquisition of privately owned AERC Recycling Solutions ... facilities and a vast array of additional technologies, services, and new markets to ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... countries to hospitals in the United States, it’s a threat that is constantly ... obstacles facing infection prevention and offers strategies for the healthcare community to help ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... -- Invivotek, LLC, a Genesis Biotechnology Group ® ... contract research organization (CRO), announced the completion of the ... research facility in Hamilton, New Jersey ... source to reduce costs and lessen the CRO facility,s ... Farm follows Invivotek,s recent expansion from a 19,712 square ...
(Date:3/24/2017)... Calif. , March 24, 2017 /PRNewswire/ ... epigenetics company, and Hamilton Robotics, Inc., who ... announced an ongoing collaboration that teams Zymo ... and RNA and DNA extraction products with ... already created optimized methods for microbiomics and ...
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
Breaking Medicine Technology: